Pharma Shockwave: Govt's Plan to Hike Medicine Costs? Experts Issue Stark Warning!

Indian pharmaceutical industry experts are raising serious concerns regarding the government's intention to implement a Minimum Import Price (MIP) for essential pharmaceutical raw materials. This proposed policy targets key inputs such as Penicillin-G (Pen-G), 6-aminopenicillanic acid (6-APA), and amoxicillin. The government's stated aim is to combat aggressive undercutting and dumping by Chinese manufacturers and to bolster domestic production infrastructure.

Industry analysts and experts believe that imposing a chain-wide MIP on these critical inputs could lead to significant negative consequences. A primary concern is the substantial increase in costs across a wide range of essential medicines. They argue that this move might disrupt existing government procurement tenders and could inadvertently concentrate the supply chain without sufficient evidence demonstrating actual dumping or import-related injury to the domestic industry.

The experts highlighted that Penicillin-G is not merely a standalone product but serves as the fundamental upstream molecule for numerous essential antibiotics. It feeds into various intermediates and high-volume formulations, including amoxicillin and multiple cephalosporins. Consequently, a price floor at the Pen-G level, or worse, encompassing 6-APA and amoxicillin, would establish a cost baseline for dozens of price-controlled formulations. These formulations are extensively used in primary healthcare and public procurement programs across the nation.

An analysis of current tenders reveals that state government procurements for amoxicillin and related combinations alone amount to approximately ₹1,012.6 crore at prevailing prices. Experts estimate that if the costs of these Active Pharmaceutical Ingredients (APIs) were to double to the proposed MIP levels, suppliers could face potential losses nearing ₹350 crore. This scenario would render multiple existing contracts economically unviable, potentially leading to significant disruptions. Past experiences have shown that similar shocks in input costs have resulted in sharp price escalations, withdrawal of bidders, and the need for re-tendering across various states.

Data suggests that Penicillin-G prices have already retreated to pre-pandemic levels, hovering around $13.5 per kg. Over the past twelve months, India imported roughly 8,000 tonnes of Pen-G and approximately 11,250 tonnes of 6-APA. These import figures significantly exceed the reported domestic production capacity for 6-APA, which stands at roughly 3,600 tonnes per annum. It is also noted that there has been a lack of substantial open-market domestic supply for Pen-G or 6-APA during the current financial year, with significant volumes transacted between related parties.

In 2020, the Indian government introduced a Production-Linked Incentive (PLI) scheme designed to attract investment in the manufacturing of critical raw materials domestically. This initiative aimed to reduce the country's heavy reliance on China and promote pricing stability. However, experts caution that imposing a high MIP on top of the PLI scheme risks creating permanent protectionist barriers. This could weaken efficiency incentives among beneficiaries and ultimately transfer increased costs to patients and public healthcare budgets. They suggest that for PLI beneficiaries facing challenges like low capacity utilization or high fixed costs, the corrective measures should focus on operational restructuring and scaling up production rather than implementing nationwide price floors on essential inputs.

The potential implementation of a Minimum Import Price on key pharmaceutical inputs could lead to increased costs for essential medicines, impacting public health budgets and potentially making life-saving treatments less accessible, particularly for the most vulnerable populations. It also introduces significant uncertainty and potential financial strain for pharmaceutical companies involved in government tenders and domestic manufacturing initiatives.
Impact Rating: 7/10

Minimum Import Price (MIP): A minimum price set by a government below which imports of a specific product are not allowed.
Penicillin-G (Pen-G): A primary antibiotic molecule used as a base for manufacturing various other antibiotics.
6-aminopenicillanic acid (6-APA): An intermediate chemical compound derived from Penicillin-G, crucial for producing semi-synthetic penicillins.
Dumping: The practice of exporting goods at a price lower than the normal value, often to gain market share unfairly.
Price-controlled formulations: Pharmaceutical products whose maximum selling prices are regulated by the government.
Production-Linked Incentive (PLI) scheme: A government scheme that provides financial incentives based on incremental sales of manufactured goods.

Instant Stock Alerts on WhatsApp